SINE-AID IB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SINE-AID IB (SINE-AID IB).
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
| Metabolism | Hepatic metabolism via CYP2C9 and glucuronidation. Minor pathways include CYP2C19 and CYP3A4. |
| Excretion | Renal excretion of unchanged drug and metabolites: ~90% renal, ~10% biliary/fecal. |
| Half-life | Terminal elimination half-life: 2-4 hours (mean ~2.5 h). In elderly or hepatic impairment, may be prolonged up to 6-8 hours. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd ~0.1-0.2 L/kg, indicating limited extravascular distribution; primarily confined to plasma and interstitial fluid. |
| Bioavailability | Oral: 85-95% (subject to first-pass metabolism); rectal suppository: ~70-80%; topical: minimal systemic absorption (<5%). |
| Onset of Action | Oral: 30-60 minutes; onset of analgesic effect typically within 1 hour. |
| Duration of Action | 4-6 hours for analgesia; antipyretic effect lasts 6-8 hours. Duration may be shorter with immediate-release formulations. |
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg per day without prescription, 2400 mg per day with prescription.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-59 mL/min: reduce dose by 50% or extend interval to every 8 hours; eGFR <30 mL/min: avoid use or maximum 200 mg every 12 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use. |
| Pediatric use | 6 months to 12 years: 5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day or 1200 mg daily (whichever lower). |
| Geriatric use | Start at lowest effective dose (200 mg every 6-8 hours); maximum 1200 mg per day; monitor renal function and gastrointestinal tolerance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SINE-AID IB (SINE-AID IB).
| Breastfeeding | Ibuprofen enters breast milk in low concentrations (M/P ratio ~0.01, relative infant dose <1% of maternal weight-adjusted dose). Considered compatible with breastfeeding; use lowest effective dose for shortest duration. |
| Teratogenic Risk | First trimester: Ibuprofen exposure associated with increased risk of cardiac septal defects and gastroschisis (OR 1.2-1.8). Third trimester: Avoid due to risk of premature ductus arteriosus constriction, oligohydramnios, and neonatal renal impairment. Overall FDA Category D for third trimester; Category C for first/second trimesters. |
■ FDA Black Box Warning
Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
| Serious Effects |
Hypersensitivity to ibuprofen or NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, active peptic ulcer or gastrointestinal bleeding, severe renal failure.
| Precautions | Cardiovascular risk (avoid in severe heart failure), gastrointestinal risk (history of peptic ulcer disease or bleeding), renal toxicity (monitor in renal impairment), hypertension, asthma exacerbation, hepatic impairment, pregnancy (avoid in third trimester). |
Loading safety data…
| Fetal Monitoring |
| Monitor amniotic fluid index (oligohydramnios risk) and fetal ductus arteriosus Doppler if used beyond 48 hours in third trimester. Maternal monitoring: renal function, blood pressure, and signs of gastrointestinal bleeding. |
| Fertility Effects | NSAIDs including ibuprofen may impair female fertility via inhibition of prostaglandin synthesis, potentially delaying or preventing ovulation. Effect is reversible upon discontinuation. |